In this upbeat interview, CEO Martin Gouldstone of Oncimmune - a leading life sciences firm providing autoantibody profiling services that are used to enable precision medicine within the Biopharma industry – takes me through today’s positive yearend trading update, 3 contract wins and exciting road ahead.
